Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Vitrafy Life Sciences's annualizedNet Income for the quarter that ended in Dec. 2025 was A$-14.25 Mil.
Vitrafy Life Sciences's average Total Assets over the quarter that ended in Dec. 2025 was A$27.76 Mil. Therefore, Vitrafy Life Sciences's annualized ROA % for the quarter that ended in Dec. 2025 was -51.32%.
The historical rank and industry rank for Vitrafy Life Sciences's ROA % or its related term are showing as below:
ASX:VFY'
s ROA % Range Over the Past 10 Years
Min: -89.4 Med: -57.31 Max: -25.22
Current: -46.39
During the past 4 years, Vitrafy Life Sciences's highest ROA % was -25.22%. The lowest was -89.40%. And the median was -57.31%.
ASX:VFY's ROA % is ranked worse than 87.92% of 2890
companies
in the Software industry
Industry Median: 1.705
vs ASX:VFY: -46.39
Vitrafy Life Sciences (ASX:VFY) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Software - Infrastructure subindustry, Vitrafy Life Sciences's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitrafy Life Sciences ROA % vs Software Industry
For the Software industry and Technology sector, Vitrafy Life Sciences's ROA % distribution charts can be found below:
* The bar in red indicates where Vitrafy Life Sciences's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Vitrafy Life Sciences (ASX:VFY) has a ROA % of -51.32% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Vitrafy Life Sciences and its competitors. According to the industry distribution chart, Vitrafy Life Sciences ranks #2541 out of 2890 companies in the Software industry, placing it in the top 87.9%.
Is Vitrafy Life Sciences' ROA % too high?
Vitrafy Life Sciences' current ROA % is -51.32%. Based on the distribution chart, Vitrafy Life Sciences ranks #2541 out of 2890 companies in the Software industry, which is in the bottom quartile relative to peers. Overall, Vitrafy Life Sciences has a GF Score™ of 5/100, reflecting its overall financial health beyond just this single metric.
How does Vitrafy Life Sciences' ROA % compare to MSFT and ORCL?
According to the Software industry distribution chart, Vitrafy Life Sciences ranks #2541 out of 2890 companies for ROA %. This places Vitrafy Life Sciences in the lower half of its industry. The industry median ROA % is 1.71. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Software company?
The median ROA % among Software companies is 1.71, based on 2,890 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Vitrafy Life Sciences and its competitors. For the Software industry, the median ROA % is 1.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitrafy Life Sciences's current ROA % is -51.32%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitrafy Life Sciences stock overvalued right now?
Vitrafy Life Sciences (ASX:VFY) has a current ROA % of -51.32%. The current ROA % is -51.32%. Vitrafy Life Sciences' overall GF Score™ is 5/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Vitrafy Life Sciences (ASX:VFY), the current ROA % is -51.32% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vitrafy Life Sciences Ltd developed a range of proprietary smart cryopreservation hardware devices and Lifechain, an integrated, cloud-based software platform, to provide a complete, vertically integrated cryopreservation solution to retain the quality of cryopreserved biomaterials. The company devices includes Vitrafy's Smart Cryopreservation Device; Vitrafy's Smart Thawing Device and Vitrafy's Smart Packaging.
5GF Score
Get the complete analysis for ASX:VFY
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VFY has been successfully added to your 
